Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Becatecarin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 12/20 | 0.49 |
| ▸ | PRKCA | P17252 | 10/20 | 0.78 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.74 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.74 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.62 |
| ▸ | PRKCG | P05129 | 1/20 | 0.62 |
| ▸ | PRKCB | P05771 | 1/20 | 0.62 |
| ▸ | PRKCH | P24723 | 1/20 | 0.62 |
| ▸ | PRKCI | P41743 | 1/20 | 0.62 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.62 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.62 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.62 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.62 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.62 |
| ▸ | EGFR | P00533 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Becatecarin SCHEMBL31237559 | 1.00 | PRKCA (0.78) | PRKCADYRK1APAX8PRKD3PRKCG | |
| Becatecarin SCHEMBL5953888 | 1.00 | PRKCA (0.78) | PRKCADYRK1APAX8PRKD3PRKCG | |
| Becatecarin SCHEMBL29378739 | 1.00 | PRKCA (0.78) | PRKCADYRK1APAX8PRKD3PRKCG | |
| Becatecarin SCHEMBL6385483 | 0.97 | PRKCA (0.74) | PRKCADYRK1APAX8PRKD3PRKCG | |
| SCHEMBL6385491 | 0.93 | PRKCA (0.67) | PRKCADYRK1APAX8PRKD3PRKCG | |
| SCHEMBL26846490 | 0.92 | PRKCA (0.65) | PRKCADYRK1APAX8PRKD3PRKCG | |
| SCHEMBL14498686 | 0.86 | PRKCA (0.57) | PRKCADYRK1APAX8PRKD3PRKCG | |
| Rebeccamycin SCHEMBL32690193 | 0.85 | DYRK1A (1.00) | PRKCADYRK1APAX8PRKD3PRKCG | |
| Rebeccamycin SCHEMBL12961242 | 0.85 | DYRK1A (1.00) | PRKCADYRK1APAX8PRKD3PRKCG | |
| Rebeccamycin SCHEMBL14069957 | 0.85 | DYRK1A (1.00) | PRKCADYRK1APAX8PRKD3PRKCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060105961-A1 | Method of using a cox-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia | PHARMACIA CORPORATION (US) | 2006-05-18 | — | — | US | claimed |
| US-20030225150-A1 | Method of using a COX-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia | PHARMACIA CORPORATION | 2003-12-04 | — | — | US | claimed |
| US-11834458-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834458-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20060105961-A1 | Method of using a cox-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia | PHARMACIA CORPORATION (US) | 2006-05-18 | — | — | US | disclosed |
| US-20030225150-A1 | Method of using a COX-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia | PHARMACIA CORPORATION | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060105961-A1 | Method of using a cox-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia | TOP2A, TOP2B, TOP1 | TOP1 3/4885PRKCA 1272/4885DYRK1A 2830/4885 |
| US-20030225150-A1 | Method of using a COX-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia | TOP2A, TOP2B, TOP1 | TOP1 3/4885PRKCA 1272/4885DYRK1A 2830/4885 |
| US-11834458-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | TOP1 531/4885PRKCA 2199/4885DYRK1A 3362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.